Tumor-Derived PGLYRP2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.
Hepatocellular carcinoma (HCC) is linked to immunosuppression. Relieving immunosuppression has been becoming an attractive strategy to improve the efficacy of cancer immunotherapy. PGLYRP2 is a pattern recognition receptor, which is specifically expressed in liver and implicated in regulation of innate immunity and immunosurveillance. However, the role of hepatic PGLYRP2 in modulating immune responses against HCC remains to be investigated. In this study, we aimed to investigate whether PGLYRP2 is able to influence HCC progression through regulating host antitumor immune responses. Here we demonstrated that PGLYRP2 was down-regulated in HCC, which was linked with poor prognosis in patients (p<0.001). PGLYRP2 overexpression in HCC cells significantly enhanced antitumor immune responses in immune-competent mice, and elevated immune response rates of PBMCs against HCC. Mechanistically, DNMT3A-mediated promoter hypermethylation was responsible for the downregulation of PGLYRP2 in HCC. PGLYRP2 promoted production of chemokine CCL5 in HCC via binding to CCL5 promoter, which contributed to the enhanced antitumor immunity. Conclusions: we provide evidence that tumor-derived PGLYRP2 acts as a candidate biomarker for adequate immune response against HCC and improved patient outcomes, indicating the importance of hepatic PGLYRP2 in cancer immunosurveillance and in designing novel immunotherapeutic approaches. This article is protected by copyright. All rights reserved.